Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer.

Arai J, Otoyama Y, Fujita KI, Goto K, Tojo M, Katagiri A, Nozawa H, Kubota Y, Takahashi T, Ishida H, Tsunoda T, Matsumoto N, Ogawa K, Nakagawa R, Muroyama R, Kato N, Yoshida H.

Open source

DOI: 10.1186/s12885-022-09512-5
Published: 2022-04-20
Container: BMC Cancer
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12885-022-09512-5,
  title = {Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer.},
  author = {Arai J and  Otoyama Y and  Fujita KI and  Goto K and  Tojo M and  Katagiri A and  Nozawa H and  Kubota Y and  Takahashi T and  Ishida H and  Tsunoda T and  Matsumoto N and  Ogawa K and  Nakagawa R and  Muroyama R and  Kato N and  Yoshida H.},
  year = {2022},
  journal = {BMC Cancer},
  doi = {10.1186/s12885-022-09512-5},
  url = {https://doi.org/10.1186/s12885-022-09512-5}
}

RIS

TY  - JOUR
TI  - Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer.
AU  - Arai J
AU  -  Otoyama Y
AU  -  Fujita KI
AU  -  Goto K
AU  -  Tojo M
AU  -  Katagiri A
AU  -  Nozawa H
AU  -  Kubota Y
AU  -  Takahashi T
AU  -  Ishida H
AU  -  Tsunoda T
AU  -  Matsumoto N
AU  -  Ogawa K
AU  -  Nakagawa R
AU  -  Muroyama R
AU  -  Kato N
AU  -  Yoshida H.
PY  - 2022
JO  - BMC Cancer
DO  - 10.1186/s12885-022-09512-5
UR  - https://doi.org/10.1186/s12885-022-09512-5
ER  -

APA

J, A., Y, O., KI, F., K, G., M, T., A, K., H, N., Y, K., T, T., H, I., T, T., N, M., K, O., R, N., R, M., N, K., & H., Y. (2022). Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer.. BMC Cancer. https://doi.org/10.1186/s12885-022-09512-5

Source records

europe-pmc · retrieved 2026-09-26T09:31:33.158Z
doaj · retrieved 2026-09-26T09:31:33.122Z
hal · retrieved 2026-09-26T09:31:33.168Z